179 related articles for article (PubMed ID: 35996397)
1. Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development.
Haque A; Sahu V; Lombardo JL; Xiao L; George B; Wolff RA; Morris JS; Rashid A; Kopchick JJ; Kaseb AO; Amin HM
J Hepatocell Carcinoma; 2022; 9():823-837. PubMed ID: 35996397
[TBL] [Abstract][Full Text] [Related]
2. Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma.
Kaseb AO; Haque A; Vishwamitra D; Hassan MM; Xiao L; George B; Sahu V; Mohamed YI; Carmagnani Pestana R; Lombardo JL; Avritscher R; Yao JC; Wolff RA; Rashid A; Morris JS; Amin HM
Front Oncol; 2022; 12():986305. PubMed ID: 36276070
[TBL] [Abstract][Full Text] [Related]
3. Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma.
Lin CC; Liu TW; Yeh ML; Tsai YS; Tsai PC; Huang CF; Huang JF; Chuang WL; Dai CY; Yu ML
Clin Mol Hepatol; 2021 Apr; 27(2):313-328. PubMed ID: 33317258
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of hepatic expression of GHR/STAT5/IGF-1 signaling pathway fosters development and aggressiveness of HCV-related hepatocellular carcinoma: Crosstalk with Snail-1 and type 2 transforming growth factor-beta receptor.
Abu El-Makarem MA; Kamel MF; Mohamed AA; Ali HA; Mohamed MR; Mohamed AEM; El-Said AM; Ameen MG; Hassnine AA; Hassan HA
PLoS One; 2022; 17(11):e0277266. PubMed ID: 36374927
[TBL] [Abstract][Full Text] [Related]
5. Hepatic leptin receptor expression can partially compensate for IL-6Rα deficiency in DEN-induced hepatocellular carcinoma.
Mittenbühler MJ; Sprenger HG; Gruber S; Wunderlich CM; Kern L; Brüning JC; Wunderlich FT
Mol Metab; 2018 Nov; 17():122-133. PubMed ID: 30224299
[TBL] [Abstract][Full Text] [Related]
6. NADPH Oxidase 1 in Liver Macrophages Promotes Inflammation and Tumor Development in Mice.
Liang S; Ma HY; Zhong Z; Dhar D; Liu X; Xu J; Koyama Y; Nishio T; Karin D; Karin G; Mccubbin R; Zhang C; Hu R; Yang G; Chen L; Ganguly S; Lan T; Karin M; Kisseleva T; Brenner DA
Gastroenterology; 2019 Mar; 156(4):1156-1172.e6. PubMed ID: 30445007
[TBL] [Abstract][Full Text] [Related]
7. [Expression of growth hormone receptor in hepatocellular carcinoma and its significance].
Liu JP; Wang HT; Ou QJ; Lu YT; Lu HP; Gao JH; Chu ZH; Zhao HY
Ai Zheng; 2003 Mar; 22(3):298-301. PubMed ID: 12654191
[TBL] [Abstract][Full Text] [Related]
8. Constitutive Notch2 signaling induces hepatic tumors in mice.
Dill MT; Tornillo L; Fritzius T; Terracciano L; Semela D; Bettler B; Heim MH; Tchorz JS
Hepatology; 2013 Apr; 57(4):1607-19. PubMed ID: 23175466
[TBL] [Abstract][Full Text] [Related]
9. TLR4 Deficiency Protects against Hepatic Fibrosis and Diethylnitrosamine-Induced Pre-Carcinogenic Liver Injury in Fibrotic Liver.
Weber SN; Bohner A; Dapito DH; Schwabe RF; Lammert F
PLoS One; 2016; 11(7):e0158819. PubMed ID: 27391331
[TBL] [Abstract][Full Text] [Related]
10. PI3Kγ promotes obesity-associated hepatocellular carcinoma by regulating metabolism and inflammation.
Becattini B; Breasson L; Sardi C; Zani F; Solinas G
JHEP Rep; 2021 Dec; 3(6):100359. PubMed ID: 34704005
[TBL] [Abstract][Full Text] [Related]
11. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer.
Schneider C; Teufel A; Yevsa T; Staib F; Hohmeyer A; Walenda G; Zimmermann HW; Vucur M; Huss S; Gassler N; Wasmuth HE; Lira SA; Zender L; Luedde T; Trautwein C; Tacke F
Gut; 2012 Dec; 61(12):1733-43. PubMed ID: 22267597
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma.
Khan MGM; Ghosh A; Variya B; Santharam MA; Ihsan AU; Ramanathan S; Ilangumaran S
BMC Cancer; 2020 Aug; 20(1):774. PubMed ID: 32807134
[TBL] [Abstract][Full Text] [Related]
13. Abberent expression of NOR1 protein in tumor associated macrophages contributes to the development of DEN-induced hepatocellular carcinoma.
Chen S; Zheng P; Wang W; Yi M; Chen P; Cai J; Li J; Peng Q; Ban Y; Zhou Y; Zeng Z; Li X; Xiong W; Li G; Xiang B
J Cell Physiol; 2018 Jun; 233(6):5002-5013. PubMed ID: 29227538
[TBL] [Abstract][Full Text] [Related]
14. The long noncoding RNA, EGFR-AS1, a target of GHR, increases the expression of EGFR in hepatocellular carcinoma.
Qi HL; Li CS; Qian CW; Xiao YS; Yuan YF; Liu QY; Liu ZS
Tumour Biol; 2016 Jan; 37(1):1079-89. PubMed ID: 26271667
[TBL] [Abstract][Full Text] [Related]
15. Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model.
Hatting M; Spannbauer M; Peng J; Al Masaoudi M; Sellge G; Nevzorova YA; Gassler N; Liedtke C; Cubero FJ; Trautwein C
Cell Death Dis; 2015 Mar; 6(3):e1667. PubMed ID: 25741592
[TBL] [Abstract][Full Text] [Related]
16. Adult mouse model of early hepatocellular carcinoma promoted by alcoholic liver disease.
Ambade A; Satishchandran A; Gyongyosi B; Lowe P; Szabo G
World J Gastroenterol; 2016 Apr; 22(16):4091-108. PubMed ID: 27122661
[TBL] [Abstract][Full Text] [Related]
17. Role of insulin receptor substrates in the progression of hepatocellular carcinoma.
Sakurai Y; Kubota N; Takamoto I; Obata A; Iwamoto M; Hayashi T; Aihara M; Kubota T; Nishihara H; Kadowaki T
Sci Rep; 2017 Jul; 7(1):5387. PubMed ID: 28710407
[TBL] [Abstract][Full Text] [Related]
18. Persistent mTORC1 activation via Depdc5 deletion results in spontaneous hepatocellular carcinoma but does not exacerbate carcinogen- and high-fat diet-induced hepatic carcinogenesis in mice.
Xu L; Yang C; Wang J; Li Z; Huang R; Ma H; Ma J; Wang Q; Xiong X
Biochem Biophys Res Commun; 2021 Nov; 578():142-149. PubMed ID: 34562654
[TBL] [Abstract][Full Text] [Related]
19. Exercise retards hepatocarcinogenesis in obese mice independently of weight control.
Arfianti A; Pok S; Barn V; Haigh WG; Yeh MM; Ioannou GN; Teoh NC; Farrell GC
J Hepatol; 2020 Jul; 73(1):140-148. PubMed ID: 32302728
[TBL] [Abstract][Full Text] [Related]
20. Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll-like receptor 2-deficient mice.
Lin H; Yan J; Wang Z; Hua F; Yu J; Sun W; Li K; Liu H; Yang H; Lv Q; Xue J; Hu ZW
Hepatology; 2013 Jan; 57(1):171-82. PubMed ID: 22859216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
